ArticleRevista do Colegio Brasileiro de Cirurgioes
Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery.
Article in Revista do Colegio Brasileiro de Cirurgioes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03341429. Cited by 38 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery
Who cites it
38 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis.Langenbeck's archives of surgery · 2025Pooled it
- Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis.International journal of obesity (2005) · 2025Pooled it
- The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: a systematic review and meta-analysis.Eating and weight disorders : EWD · 2025Pooled it
- Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.Obesity surgery · 2025Pooled it
- Adjuvant Glucose-Like Peptide 1 Receptor Agonist Therapy for Suboptimal Weight Loss After Bariatric Surgery: a Systematic Review.Obesity surgery · 2024Pooled it
- Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.Obesity surgery · 2024Pooled it
- The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review.Obesity (Silver Spring, Md.) · 2023 · on this mapPooled it
- European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.United European gastroenterology journal · 2022Guideline
- Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.EClinicalMedicine · 2026Article
- Beyond surgery: a multimodal framework for a pediatric metabolic and bariatric surgery program in a safety-net children's hospital.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2026Article
- Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels.International journal of obesity (2005) · 2025Review
- Weight Loss Pharmacotherapy: Current and Future Therapies.Gastrointestinal endoscopy clinics of North America · 2024Review
- Review
- Weight Regain after Metabolic Surgery: Beyond the Surgical Failure.Journal of clinical medicine · 2024Review
- Challenges in the care and treatment of patients with extreme obesity.Archives of endocrinology and metabolism · 2024Review
- Weight loss maintenance after bariatric surgery.World journal of clinical cases · 2023Review
- [Pharmacotherapy of obesity-Competition to bariatric surgery or a meaningful supplement?]Chirurgie (Heidelberg, Germany) · 2023Review
- Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment.Current diabetes reports · 2023Review
- The efficacy of liraglutide combined with intragastric balloon on weight loss.Revista da Associacao Medica Brasileira (1992) · 2023Article
- High-dose liraglutide improves metabolic syndrome in poor responders to bariatric surgery.Frontiers in nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the results of the use of liraglutide in a group of patients undergoing surgical treatment of morbid obesity with unsatisfactory weight loss or regain of more than 15% of minimum reached weight.
methodsThe authors conducted a retrospective analysis of 15 operated patients who had excess weight loss <50% after two years of follow-up or regained weight more than 15% of the minimum reached weight. We included only patients who had the expected "surgical anatomy", assessed by contrast radiography and endoscopy. Mean age was 47.2 ± 12.5 years, and patients received liraglutide at doses from 1.2 to 3.0 mg/day for eight to 28 weeks follow-up.
resultsSurgical treatment induced a weight loss of 34.1 ± 16.5 kg. The average weight regain after 5.3 ± 3.3 years was 14.2 ± 12.1 Kg. The average weight was significantly reduced after treatment with liraglutide (100.9 ± 18.3 kg. vs Kg 93.5 ± 17.4, p <0.0001). Six patients had nausea and two discontinued therapy due to the cost of medication.
conclusionmedical treatment directed to the control of satiety using liraglutide may be an alternative treatment of patients with poor weight loss or weight regain after surgery when no technical problem has been identified.
Indexed as
Identifiers
23912365What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.